Vaccines as a remedy for antimicrobial resistant bacterial infections

Projektinformationen

vAMRes

ID Finanzhilfevereinbarung: 787552

DOI 10.3030/787552

Abgeschlossenes Projekt

EK-Unterschriftsdatum 4 September 2018

Startdatum 1 November 2018

Enddatum 31 Oktober 2023

Finanziert unter

• EXCELLENT SCIENCE - European Research Council (ERC)

Gesamtkosten € 2 432 500,00

EU-Beitrag € 2 432 500,00

Koordiniert durch

FONDAZIONE TOSCANA LIFE SCIENCES
Italy

Ziel

Antimicrobial Resistance (AMR) is perhaps the most emerging alarm in health. It already causes 700,000 deaths per year and the forecast for 2050 is 10 million deaths, more than cancer today. WHO, UN General Assembly, World Bank, G20, EU, UK and USA governments call for new antibiotics, but the pipeline for new antibiotics is not very promising. Here we propose to use new technologies to develop human monoclonal antibodies and vaccines against three AMR bacteria such as gonococcus, pneumococcus and E.coli. The technology defined as reverse vaccinology 2.0 already successful for viral infections, will be used for bacterial vaccines. Taking advantage of the recent possibility of high throughput cloning of human B cells from convalescent or vaccinated people we aim to find targets difficult or impossible to be discovered using conventional technologies. B cells will be cloned from people convalescent from target infections and from people vaccinated with Men B vaccine which confers some protection against gonococcus. The antibodies produced by the clones will be screened for their ability to bind, intoxicate or kill bacteria using a novel high-throughput microscopy platform that rapidly captures digital images and also with conventional, lower throughput technologies such as bactericidal, opsono-phagocytosis and FACS assays. The selected antibodies, will be expressed as full length and used for passive immunization in animal models and tested for protection in vivo. Finally, those antibodies that will provide the best protection in the above assays, will be used to identify the recognized antigens. Selected antigens will be expressed and tested in vaccine formulations. Fab fragments can be used to make co-crystals with the antigen and determine the crystal structure of the new antigens, for the development of structure-based antigen design. In conclusion we expect to enable development of human monoclonal antibodies and vaccines against AMR.

Wissenschaftliches Gebiet

• natural sciences › biological sciences › microbiology › bacteriology
• medical and health sciences › basic medicine › immunology › immunisation
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Schlüsselbegriffe

• Vaccines
• Infectious Diseases
• Monoclonal antibodies
• Antimicrobial resistance (AMR)

Programm/Programme

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme

Thema/Themen

• ERC-2017-ADG - ERC Advanced Grant

Aufforderung zur Vorschlagseinreichung

ERC-2017-ADG

Finanzierungsplan

ERC-ADG - Advanced Grant

Gastgebende Einrichtung

FONDAZIONE TOSCANA LIFE SCIENCES

• Netto-EU-Beitrag: € 2 432 500,00
• Adresse: VIA FIORENTINA 1 ; 53100 Siena ; Italien
• Region: Centro (IT) › Toscana › Siena
• Aktivitätstyp: Research Organisations
• Gesamtkosten: € 2 432 500,00

Begünstigte (1)

FONDAZIONE TOSCANA LIFE SCIENCES

Italien

• Netto-EU-Beitrag: € 2 432 500,00
• Adresse: VIA FIORENTINA 1 ; 53100 Siena
• Region: Centro (IT) › Toscana › Siena
• Aktivitätstyp: Research Organisations
• Gesamtkosten: € 2 432 500,00